Cutaneous vasculitis is inflammation of the small blood vessels in the skin, driven by an immune reaction that damages vessel walls and produces a range of skin lesions, most characteristically raised, reddish-purple spots on the lower legs known as palpable purpura. It is not a single disease but a pattern that shows up across dozens of conditions, from drug reactions and infections to autoimmune disorders and, occasionally, cancers. The term describes where the inflammation is happening and what it looks like under a microscope, but the hard work for doctors and patients is figuring out why it is happening and whether it extends beyond the skin.
What Happens Inside the Blood Vessels
The core process in most cutaneous vasculitis starts with immune complexes, which are clumps of antibodies bound to whatever the immune system has flagged as a threat. These complexes settle into the walls of small blood vessels in the skin, where they trigger activation of the complement system, a cascade of proteins that amplifies inflammation.1PubMed Central. Cutaneous Vasculitis and Recurrent Infection Caused by Deficiency in Complement Factor I The complement cascade attracts neutrophils, which pile into the vessel wall. As those neutrophils die and break apart, their nuclear debris scatters through the tissue. Pathologists call this fragmentation “leukocytoclasia,” and finding it on a skin biopsy, alongside fibrinoid necrosis of the vessel wall, is the hallmark that confirms the diagnosis.2PubMed Central. Diagnosis and management of leukocytoclastic vasculitis The swelling and structural damage to the vessel wall is what allows red blood cells to leak into the surrounding tissue, producing the purpura you see on the skin surface.3PubMed. Vasculitides and the Complement System: a Comprehensive Review
What It Looks Like
The signature presentation is palpable purpura, small raised spots that range from pinpoint to a few centimeters across, typically appearing symmetrically on the lower legs and ankles.4PubMed. A practical approach to the diagnosis, evaluation, and management of cutaneous small-vessel vasculitis Unlike a simple bruise or a flat rash, these spots feel slightly elevated when you run a finger over them, and they do not blanch when pressed. Gravity matters here: the lower extremities bear the brunt because blood pools in those vessels while you are standing or sitting, which encourages immune complex deposition.
That said, purpura is not the only way cutaneous vasculitis appears. Depending on the size of the blood vessels involved and the underlying cause, lesions can include hives that linger far longer than ordinary hives, painful nodules under the skin, blisters, ulcers, or a lace-like discoloration called livedo reticularis. Some people have lesions above the waist or on the arms, especially when the vasculitis is part of a systemic condition rather than a localized reaction. The variety of presentations is part of what makes this diagnosis tricky.
Common Triggers and Causes
In many cases, a trigger can be identified, and drugs and infections account for the majority. Antibiotics (especially beta-lactams and sulfonamides), NSAIDs, and diuretics are among the medications most frequently linked to cutaneous vasculitis. Drug-induced cases can range from mild, skin-limited purpura to extensive necrosis with serious systemic involvement.5PubMed Central. Drug-induced cutaneous vasculitis and anticoagulant-related cutaneous adverse reactions Infections, particularly upper respiratory tract infections, are another common precipitant, and hepatitis B, hepatitis C, and streptococcal infections deserve specific mention because they drive immune complex formation aggressively.
Autoimmune and connective tissue diseases are the next large category. Lupus, rheumatoid arthritis, and Sjögren syndrome all predispose people to cutaneous vasculitis because chronic immune activation generates a steady supply of circulating immune complexes. In a smaller but clinically important group, cutaneous vasculitis turns out to be a paraneoplastic phenomenon, meaning it appears as a consequence of an underlying cancer. In one population-based study, about 4% of adult patients with cutaneous vasculitis were eventually found to have a malignancy, split between blood cancers and solid tumors, and these patients tended to be older, with a mean age near 68.6PubMed Central. The Spectrum of Paraneoplastic Cutaneous Vasculitis in a Defined Population Incidence and Clinical Features
Despite thorough workups, around half of all cutaneous vasculitis cases remain idiopathic, meaning no specific cause is found. That is frustrating for patients but not necessarily alarming; idiopathic cases are often self-limited and resolve within weeks to months.
Major Subtypes Worth Knowing
Because cutaneous vasculitis is a pattern rather than one disease, several recognized subtypes deserve their own discussion. They differ in the size of the vessels affected, the type of immune deposit involved, and the risk of systemic complications.
IgA Vasculitis (Henoch-Schönlein Purpura)
IgA vasculitis is the most common systemic vasculitis in children, typically appearing after an upper respiratory infection and presenting with purpura on the legs and buttocks, joint pain, abdominal pain, and sometimes kidney involvement.7PubMed Central. IgA Vasculitis (Henoch–Schönlein Purpura): An Update on Treatment In children, the prognosis is usually excellent, with most cases resolving on their own. Adults can develop IgA vasculitis too, but the story is different: kidney involvement is more frequent, tends to be more severe, and roughly 10 to 30% of adults with IgA vasculitis nephritis eventually progress to end-stage kidney disease.
A study comparing adults and children with IgA vasculitis found that adults had higher rates of kidney involvement at the time of diagnosis, were more likely to need corticosteroids or immunosuppressive drugs, and had more relapses. Children, by contrast, more frequently recovered completely without treatment.8PubMed. Comparing immunoglobulin A vasculitis (Henoch-Schönlein purpura) in children and adults This age-based divergence in outcomes means that any adult diagnosed with IgA vasculitis needs careful monitoring of kidney function, even if the skin lesions seem mild.
Urticarial Vasculitis
Urticarial vasculitis looks, at first glance, like ordinary hives. The key difference is that individual wheals persist for 24 hours or longer and often leave behind faint brownish discoloration when they fade, rather than disappearing without a trace the way typical hives do.9PubMed Central. Urticarial vasculitis Most cases are idiopathic, but urticarial vasculitis has been linked to drugs, infections, autoimmune connective tissue diseases, and rarely, blood disorders or cancers. When it extends beyond the skin, it tends to affect the joints, kidneys, lungs, and gastrointestinal tract. If you have been diagnosed with chronic hives that do not respond to antihistamines and leave behind residual marks, urticarial vasculitis should be on the radar.
Cutaneous Polyarteritis Nodosa
Unlike the subtypes above, cutaneous polyarteritis nodosa (CPN) affects small and medium-sized arteries rather than the tiniest vessels. It presents with tender subcutaneous nodules, livedo reticularis, ulcers, and sometimes digital gangrene, without the systemic organ involvement seen in classic polyarteritis nodosa.10PubMed Central. Cutaneous polyarteritis nodosa: A rare isolated cutaneous vasculitis It is a rare condition, and its relapsing course can be discouraging, but the fact that it stays confined to the skin and adjacent nerves and muscles is reassuring. Peripheral neuropathy and muscle pain in the area around the skin lesions can occur, but involvement of distant organs is not expected.11PubMed Central. Cutaneous polyarteritis nodosa: an update
ANCA-Associated Vasculitis With Skin Involvement
The ANCA-associated vasculitides, a group of conditions in which the immune system produces antibodies against components of the neutrophils themselves, primarily affect the lungs, kidneys, and upper airways. However, skin lesions can appear during the course of the disease or even as the very first sign, making the dermatologist occasionally the first specialist to catch what is actually a systemic disease.12PubMed. Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis The skin findings in ANCA-associated vasculitis are highly variable, spanning purpura, nodules, ulcers, and more, and diagnosis requires integrating the skin biopsy results with blood tests and the clinical picture. One complicating detail: a meaningful number of patients with biopsy-confirmed ANCA-associated vasculitis in the skin test negative on ANCA blood work, so a negative test alone should not be used to rule it out.13PubMed. Cutaneous manifestations of ANCA-associated vasculitis: a retrospective review of 211 cases
How It Is Diagnosed
Confirming cutaneous vasculitis almost always requires a skin biopsy. The pathologist looks for the hallmarks already described: neutrophils infiltrating and destroying the blood vessel walls, fibrinoid necrosis, and nuclear debris. Timing matters more than most people realize. The diagnostic yield of a biopsy is highest when the sample is taken within the first 24 to 48 hours of a lesion appearing.14PubMed Central. Leukocytoclastic Vasculitis: An Early Skin Biopsy Makes a Difference After that window, the neutrophilic infiltrate can be replaced by lymphocytes and other cells, and the picture becomes less specific. If you develop new purpuric lesions, getting biopsied promptly rather than “waiting to see if it goes away” can save time and avoid diagnostic confusion.
Beyond the standard biopsy, a technique called direct immunofluorescence (DIF) can add valuable information. DIF uses antibody-tagged fluorescent dyes to detect which immune molecules are deposited in the vessel walls. In one large series, DIF was positive in about 70% of samples, with complement component C3 being the most common deposit, followed by IgA, IgM, and IgG in varying proportions depending on the underlying disease.15PubMed. Clinicopathologic correlation of 282 leukocytoclastic vasculitis cases in a tertiary hospital Finding IgA deposits points strongly toward IgA vasculitis, while IgM deposits tend to correlate with underlying autoimmune or inflammatory diseases. In another study, DIF confirmed the clinical suspicion of IgA vasculitis (Henoch-Schönlein purpura) in about 62% of suspected cases and identified an additional 20 unsuspected cases of IgA vasculitis that would have been missed without the test.16PubMed. Role of Direct Immunofluorescence in Cutaneous Small-Vessel Vasculitis DIF is not always done routinely, but it is especially useful when the subtype is unclear or when lupus or IgA vasculitis is in the differential.
Once the biopsy confirms vasculitis, a broader workup follows. Blood tests typically include markers of inflammation, kidney function, urinalysis, hepatitis serologies, complement levels, autoimmune antibodies, and ANCA. The goal is twofold: find the trigger if one exists, and check whether the inflammation has spread to internal organs.
Conditions That Look Like Vasculitis but Are Not
Several conditions can convincingly mimic cutaneous vasculitis on the skin surface. Calciphylaxis, a serious condition seen in patients with kidney failure, produces painful purpuric lesions and skin necrosis that can closely resemble vasculitis, but biopsy reveals calcification of blood vessels rather than inflammatory destruction.17Seminars in Arthritis and Rheumatism. Calciphylaxis: A Pseudo-Vasculitis Syndrome Cholesterol crystal embolism, in which tiny fragments of atherosclerotic plaque shower into small vessels and block them, can also produce livedo reticularis and purpura that look vasculitic. Cardiac myxomas, rare tumors of the heart, sometimes shower emboli that mimic the skin findings of vasculitis as well.18PubMed. Other forms of vasculitis and pseudovasculitis The treatments for these pseudovasculitis conditions are completely different from those used for true vasculitis, so getting the distinction right on biopsy is not academic; it directly changes what happens next.
Treatment Approaches
Treatment for cutaneous vasculitis depends on three things: how severe the skin involvement is, whether an underlying cause has been found, and whether there is any systemic organ involvement. When a drug or infection is the clear trigger, removing the offending medication or treating the infection can resolve the vasculitis entirely. Many mild, idiopathic cases are managed with leg elevation, compression stockings, avoidance of prolonged standing, and nonsteroidal anti-inflammatory drugs for symptom relief. Colchicine and dapsone are used for cases that persist or recur but remain confined to the skin.
Severe or refractory cutaneous disease, or any case with systemic involvement, typically requires systemic corticosteroids and sometimes stronger immunosuppressive medications such as azathioprine, methotrexate, or cyclophosphamide.19PubMed. Clinical approach to cutaneous vasculitis For systemic vasculitis with a high risk of organ damage, a combination of corticosteroids and cyclophosphamide has long been a standard regimen, though newer biologic agents are increasingly used in specific subtypes. The therapeutic ladder is roughly: supportive care and trigger removal at the bottom, then colchicine or dapsone, then systemic steroids, then immunosuppressants, escalating stepwise as severity demands.
Quality of Life and the Burden That Is Easy to Overlook
Even when cutaneous vasculitis stays confined to the skin and never threatens an organ, its impact on daily life can be substantial. A study that assessed health-related quality of life in patients with cutaneous vasculitis found that about three-quarters had severely or very severely diminished quality of life overall. The emotional domain was hit hardest, with nearly 78% of patients scoring in the severe range, followed by symptoms at about 79% and functional impairment at roughly 61%.20JAMA Dermatology. Assessment of Cutaneous Vasculitis and Quality of Life On a broader health survey, patients scored below average in six of eight domains. Greater disease severity and more recent diagnosis were both associated with worse quality of life. The message is clear: dismissing cutaneous vasculitis as “just a skin thing” misses the reality of living with a condition that is painful, visible, unpredictable, and often poorly understood by friends, employers, and sometimes even clinicians.
Nailfold Capillaroscopy and Other Emerging Tools
One area of active research is whether noninvasive methods can help monitor cutaneous vasculitis without repeated biopsies. Nailfold capillaroscopy (NFC), a technique that uses magnification to examine the tiny blood vessels at the base of the fingernail, has shown promise. In patients with vasculitis, NFC reveals microvascular changes that tend to be more severe when there is systemic involvement, underlying comorbidities, or ulcerative lesions.21PubMed Central. Nailfold Capillaroscopic (NFC) Changes in Vasculitis and Their Correlation with Systemic Involvement Preliminary data suggest that repeated NFC examinations over time could help track disease activity, potentially flagging flares before they become clinically obvious. Automated software for counting capillaries and advanced techniques that measure blood flow through the nail bed are being developed to improve accuracy and reproducibility. The evidence is still early and comes from small studies, so NFC is not yet a standard part of the vasculitis workup, but it points toward a future where monitoring these conditions could be less invasive and more informative.
When Skin Vasculitis Signals Something Deeper
For most people with cutaneous vasculitis, the disease stays in the skin and eventually resolves. But the percentage of cases that turn out to have systemic involvement, while a minority, is not negligible. In one large series of biopsy-confirmed leukocytoclastic vasculitis, about 13% of patients had systemic involvement.22PubMed. Clinicopathologic correlation of 282 leukocytoclastic vasculitis cases in a tertiary hospital Kidney involvement is the complication clinicians worry about most, because it can progress silently. Blood in the urine, protein in the urine, or rising creatinine levels are red flags that should prompt more aggressive treatment and closer follow-up.
The practical takeaway is that a diagnosis of cutaneous vasculitis is not the end of the workup but the beginning. Even patients whose skin is the only visible site of disease need at least basic blood tests and urinalysis to screen for hidden organ involvement. Repeat monitoring is appropriate for anyone with a chronic or relapsing course, with IgA vasculitis in adults, or with biopsy features suggesting an ANCA-associated process. When the skin findings are the first clue to a systemic vasculitis that has not yet declared itself in other organs, the dermatologist who biopsies early and the clinician who orders the right follow-up labs can meaningfully change the course of the disease.